Dendreon Corp fka DNDNQ

[walldiver]

The Cancer Letter only interviewed biostatisticians for the rebuttal on that one point...I would imagine that many physicians would criticize the conclusion that "close but no cigar" on the 0.052 ttp p value argument is weak, when the survival p value of 0.01 is taken together with the ttp p value. These are actual patients we are talking about here, and the ttp endpoint has been subsequently discredited as an ideal surrogate for survival in HRPC. If the recent theory about cancer vaccines killing tumors from the inside, promulgated by Dr. Dranoff, is true, then the biostatisticians' argument goes out the window.